Vivos Therapeutics Secures Extension for Critical $4.5M Debt-to-Equity Conversion
VVOS is trading near its 52-week low of $0.45 (12% above the low) on light trading volume (0.3× avg).
Summary
Vivos Therapeutics has extended its strategic financing agreement with Streeterville Capital until August 31, 2026, reaffirming Streeterville's commitment to convert up to $4.5 million of debt into equity. This follows the binding agreement announced on June 5th and detailed in the June 8th 8-K. The extension provides Vivos more time to raise the required $2.6 million in equity, which is crucial for strengthening its stockholders' equity and maintaining Nasdaq listing compliance. The company's Q1 2026 10-Q had reiterated a 'going concern' warning and Nasdaq delisting risk. Vivos plans to commence a rights offering during this extended period.
At the time of this announcement, VVOS was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $0.45 to $7.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.